Identification
- Summary
N-(2-Aminoethyl)-1-aziridineethanamine is an experimental ACE2 inhibitor for the treatment of cardiovascular disease and Severe Acute Respiratory Syndrome.
- Generic Name
- N-(2-Aminoethyl)-1-aziridineethanamine
- DrugBank Accession Number
- DB15643
- Background
First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease and its activity against Severe Acute Respiratory Syndrome (SARS).1
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for N-(2-Aminoethyl)-1-aziridineethanamine (DB15643)
- Weight
- Average: 129.207
Monoisotopic: 129.126597495 - Chemical Formula
- C6H15N3
- Synonyms
- N-(2-((2-Aminoethyl)amino)ethyl)aziridine
- N-(2-aminoethyl)-1 aziridine-ethanamine
Pharmacology
- Indication
This experimental drug was being researched for its use in the treatment of cardiovascular disease and SARS-CoV infections.1
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Angiotensin II constricts coronary blood vessels and is positively inotropic, which under normal circumstances, would increase vascular resistance and oxygen consumption.2 This action can eventually lead to myocyte hypertrophy and vascular smooth muscle cell proliferation.2 N-(2-Aminoethyl)-1-aziridineethanamine may inhibit ACE2, preventing these actions from occurring.1
N-(2-Aminoethyl)-1-aziridineethanamine binding to ACE2 may lead to a conformational change in ACE2, shifting the residues that would bind SARS-CoV S-glycoprotein, preventing viral attachment and entry.1
Target Actions Organism UAngiotensin-converting enzyme 2 inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- K93WMR7E2S
- CAS number
- 23435-23-6
- InChI Key
- XJNAQZHMIAKQOK-UHFFFAOYSA-N
- InChI
- InChI=1S/C6H15N3/c7-1-2-8-3-4-9-5-6-9/h8H,1-7H2
- IUPAC Name
- (2-aminoethyl)[2-(aziridin-1-yl)ethyl]amine
- SMILES
- NCCNCCN1CC1
References
- General References
- Huentelman MJ, Zubcevic J, Hernandez Prada JA, Xiao X, Dimitrov DS, Raizada MK, Ostrov DA: Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension. 2004 Dec;44(6):903-6. doi: 10.1161/01.HYP.0000146120.29648.36. Epub 2004 Oct 18. [Article]
- Goa KL, Balfour JA, Zuanetti G: Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs. 1996 Oct;52(4):564-88. doi: 10.2165/00003495-199652040-00011. [Article]
- Laurent S: Antihypertensive drugs. Pharmacol Res. 2017 Oct;124:116-125. doi: 10.1016/j.phrs.2017.07.026. Epub 2017 Aug 2. [Article]
- External Links
- ChemSpider
- 89317
- BindingDB
- 50233798
- ChEMBL
- CHEMBL398940
- ZINC
- ZINC000019366387
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 400.0 mg/mL ALOGPS logP -1.4 ALOGPS logP -1.1 Chemaxon logS 0.49 ALOGPS pKa (Strongest Basic) 9.78 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 41.06 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 38.69 m3·mol-1 Chemaxon Polarizability 15.71 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-13 and dynorphin...
- Gene Name
- ACE2
- Uniprot ID
- Q9BYF1
- Uniprot Name
- Angiotensin-converting enzyme 2
- Molecular Weight
- 92462.4 Da
References
- Huentelman MJ, Zubcevic J, Hernandez Prada JA, Xiao X, Dimitrov DS, Raizada MK, Ostrov DA: Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension. 2004 Dec;44(6):903-6. doi: 10.1161/01.HYP.0000146120.29648.36. Epub 2004 Oct 18. [Article]
Drug created at March 23, 2020 18:20 / Updated at June 12, 2020 16:53